Industry Trends

Heart failure affects over five million people annually in the U.S. alone and is the costliest cardiovascular illness, with upwards of $30 billion spent on managing heart failure each year. Cardiac rhythm management devices, such as pacemakers, ICDs and CRT devices, are implanted in patients with arrhythmias to correct cardiac pacing and/or to restart the heart after a sudden cardiac event. Sudden cardiac arrest (SCA) is one of the leading causes of death in the U.S. and is responsible for over 350,000 deaths annually. The chance of survival increases if defibrillation is delivered to the patient within ten minutes of the SCA event.

In 2018, the total market for cardiac rhythm management, electrophysiology and ablation devices experienced an increase over the previous year. Since these devices are critical life-saving apparatuses, the aging global population means continued market growth for all market segments in this report, with particularly strong growth in the electrophysiology (EP) and ablation markets. Over the forecast period, the market will maintain growth at a CAGR of in the single-digits.

Report Regional Coverage

Throughout this research series, iData has covered several countries in great detail. Each country may be purchased as a stand-alone report, tailoring the data to your needs. The covered countries are:

• • United States
  • Europe (5 countries including: Germany, France, U.K., Italy and Spain)
  • Asia-Pacific

The Only Medical Device Market Research With:
✔ Unit Sales Growth Analysis ✔ Average Selling Prices ✔ Competitor Shares by Segment & Country ✔ SKU-Level Research Methods ✔ The Lowest Acquisition Cost	Request a FREE Sample Report

Highly Detailed Segmentation

While this report suite contains all applicable cardiac rhythm management market data, each of the market segments are also available as stand alone MedCore reports. This allows you to get access to only the cardiac rhythm management market research that you need. You can view all these included reports and segmentation here:

• Procedure Volumes for Cardiac Rhythm Management, Electrophysiology & Cardiac Ablation Procedures – MedPro
• Implantable Cardioverter Defibrillator Market – MedCore
• Cardiac Resynchronization Therapy Device Market – MedCore
• Cardiac Leads Market – MedCore
• Electrocardiography Monitoring Market – MedCore
• Lab Systems Market – MedCore
• Diagnostic Electrophysiology Catheters Market – MedCore
• Cardiac Ablation Market – MedCore

Buying these reports together in this suite package will provide you with substantial discounts from the separate prices. Request Pricing to Learn More

Data Types Included

• Unit Sales, Average Selling Prices, Market Value & Growth Trends
• Procedure Volume Analysis and Trends
• 10 Year Scope and Forecast Range
• Market Drivers & Limiters for Each  Segment
• Competitive Analysis with Market Shares for Each Segment
• Recent Mergers & Acquisitions
• Disease Overviews and Demographic Information
• Company Profiles, Product Portfolios and SWOT for Top Competitors

Cardiac Rhythm Management Market Share Insights

Medtronic leads the way in both the United States and European cardiac rhythm management markets. In 2018, Medtronic led the total U.S. market for cardiac rhythm management (CRM), electrophysiology (EP) and ablation devices, due to its strength in the pacemaker, ICD and CRT segments. Medtronic has been able to retain their position in the cardiac rhythm management market through brand recognition, strong customer support and a large sales force.

Other major competitors in the market include Biotronik, Boston Scientific, Abbott and the Sorin Group. Certain companies, such as Boston Scientific, also offer a wide range of electrophysiology (EP) and cardiac ablation products and sell them through large distribution networks.

Latest Market Developments

March 2019 – FDA approved 6 MRI-safe devices by Biotronik for treating and resynchronizing tachycardia and arrhythmias

February 2019 – Johnson & Johnson acquires Auris Health Inc. and its Sensei® Robotic catheter control system

January 2019 – Abbott receives FDA approval for its TactiCath™ SE ablation catheter

November 2018 – FDA issued a Class 2 recall notice for reprocessed LASSO NAV eco EP catheters reprocessed by Stryker